pharmaceutical technology

Summary

Summary: The application of scientific knowledge or technology to pharmacy, pharmacology, and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures and in the treatment of patients.

Top Publications

  1. ncbi Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min
    Virgil A Marple
    Particle Calibration Laboratory, Mechanical Engineering Department, University of Minnesota, Minneapolis, Minnesota, USA
    J Aerosol Med 17:335-43. 2004
  2. ncbi Computational prediction of human drug metabolism
    Sean Ekins
    GeneGo, Inc, 500 Renaissance Drive, Suite 106, St Joseph, MI 49085, USA
    Expert Opin Drug Metab Toxicol 1:303-24. 2005
  3. ncbi MALDI-MS-based imaging of small molecules and proteins in tissues
    Michelle L Reyzer
    Mass Spectrometry Research Center, Vanderbilt University, Room 9160, Medical Research Building III, Nashville, TN 37232 8575 USA
    Curr Opin Chem Biol 11:29-35. 2007
  4. ncbi Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy
    Gregory S Walker
    Pfizer, Pharmacokinetics, Dynamics and Metabolism, Ann Arbor, Michigan 48015, USA
    Chem Res Toxicol 20:876-86. 2007
  5. ncbi Laser diffractometry and cascade impaction for nebulizer product characterization
    J P Mitchell
    Trudell Medical International, 725 Third Street, London, Canada N5V 5G4
    Pharmeur Sci Notes 2006:49-52. 2006
  6. ncbi Spray drying technique: II. Current applications in pharmaceutical technology
    Krzysztof Sollohub
    Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk, Poland
    J Pharm Sci 99:587-97. 2010
  7. ncbi Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain
    Nunzio Denora
    Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
    Curr Top Med Chem 9:182-96. 2009
  8. ncbi Electrostatic charge characteristics of aerosols produced from metered dose inhalers
    Philip Chi Lip Kwok
    Faculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia
    J Pharm Sci 94:2789-99. 2005
  9. ncbi Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide
    A David Woolfson
    School of Pharmacy, Queen s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
    Int J Pharm 325:82-9. 2006
  10. ncbi Systems biology in drug discovery
    Eugene C Butcher
    Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine, Stanford, California 94305 5324, USA
    Nat Biotechnol 22:1253-9. 2004

Detail Information

Publications226 found, 100 shown here

  1. ncbi Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min
    Virgil A Marple
    Particle Calibration Laboratory, Mechanical Engineering Department, University of Minnesota, Minneapolis, Minnesota, USA
    J Aerosol Med 17:335-43. 2004
    ....
  2. ncbi Computational prediction of human drug metabolism
    Sean Ekins
    GeneGo, Inc, 500 Renaissance Drive, Suite 106, St Joseph, MI 49085, USA
    Expert Opin Drug Metab Toxicol 1:303-24. 2005
    ..This will ultimately aid in hypothesis generation and the early triaging of molecules likely to have undesirable predicted properties or measured effects on key proteins and cellular functions...
  3. ncbi MALDI-MS-based imaging of small molecules and proteins in tissues
    Michelle L Reyzer
    Mass Spectrometry Research Center, Vanderbilt University, Room 9160, Medical Research Building III, Nashville, TN 37232 8575 USA
    Curr Opin Chem Biol 11:29-35. 2007
    ....
  4. ncbi Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy
    Gregory S Walker
    Pfizer, Pharmacokinetics, Dynamics and Metabolism, Ann Arbor, Michigan 48015, USA
    Chem Res Toxicol 20:876-86. 2007
    ..This is particularly important, as we often have limited supply of early discovery compounds to conduct in vivo studies to generate sufficient quantities of acyl glucuronides for further characterization...
  5. ncbi Laser diffractometry and cascade impaction for nebulizer product characterization
    J P Mitchell
    Trudell Medical International, 725 Third Street, London, Canada N5V 5G4
    Pharmeur Sci Notes 2006:49-52. 2006
    ..9.44 "Preparations for Nebulization" for the European Pharmacopeia, as well as assist in the development of a proposed International Standard (ISO 27427) for nebulizing systems...
  6. ncbi Spray drying technique: II. Current applications in pharmaceutical technology
    Krzysztof Sollohub
    Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk, Poland
    J Pharm Sci 99:587-97. 2010
    This review presents current applications of spray drying in pharmaceutical technology. The topics discussed include the obtention of excipients and cospray dried composites, methods for increasing the aqueous solubility and ..
  7. ncbi Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain
    Nunzio Denora
    Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
    Curr Top Med Chem 9:182-96. 2009
    ..of some recent approaches for the treatment of brain pathologies examining both medicinal chemistry and pharmaceutical technology contributions...
  8. ncbi Electrostatic charge characteristics of aerosols produced from metered dose inhalers
    Philip Chi Lip Kwok
    Faculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia
    J Pharm Sci 94:2789-99. 2005
    ..The results may have practical significance on lung deposition of MDI aerosols and regulatory aspects of generic aerosol products...
  9. ncbi Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide
    A David Woolfson
    School of Pharmacy, Queen s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, UK
    Int J Pharm 325:82-9. 2006
    ..TMC 120 release profiles and the mechanical properties of rings could be modified by the physicochemical nature of hydrophobic and hydrophilic excipients incorporated into the IVRs...
  10. ncbi Systems biology in drug discovery
    Eugene C Butcher
    Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine, Stanford, California 94305 5324, USA
    Nat Biotechnol 22:1253-9. 2004
    ..These systems biology approaches promise to improve decision making in pharmaceutical development...
  11. ncbi The state of innovation in drug development
    I Kola
    Schering Plough Corporation, Kenilworth, New Jersey, USA
    Clin Pharmacol Ther 83:227-30. 2008
    ..Because drug development has been stagnant in terms of innovation, there exists huge potential for innovation. Failure to innovate drug development will render the "big pharma" model unsustainable...
  12. ncbi Evaluation of injection moulding as a pharmaceutical technology to produce matrix tablets
    Thomas Quinten
    Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium
    Eur J Pharm Biopharm 71:145-54. 2009
    ..Raman spectroscopy demonstrated that the drug is distributed in the entire matrix, however, some drug clusters were identified...
  13. ncbi An in silico transwell device for the study of drug transport and drug-drug interactions
    Lana X Garmire
    Graduate Group in Comparative Biochemistry, University of California, Berkeley, California, USA
    Pharm Res 24:2171-86. 2007
    ..Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions...
  14. ncbi Implications of pharmacogenomics for drug development and clinical practice
    Geoffrey S Ginsburg
    Department of Medicine, School of Medicine, Center for Genomic Medicine, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    Arch Intern Med 165:2331-6. 2005
    ..Although the potential of these technologies is driving change in the development of clinical sciences, it remains to be seen which health care systems level needs will be addressed...
  15. ncbi Can cell systems biology rescue drug discovery?
    Eugene C Butcher
    Department of Pathology, Stanford University, Stanford, California 94305 5324, USA
    Nat Rev Drug Discov 4:461-7. 2005
    ..Drug discovery through cell systems biology could significantly reduce the time and cost of new drug development...
  16. pmc Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation
    Jenny Y Chien
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    AAPS J 7:E544-59. 2005
    ..Selected works of PK/PD modeling and simulation from preclinical to phase III are presented as case examples in this article...
  17. ncbi A functional approach to transcriptome profiling: linking gene expression patterns to metabolites that matter
    Cindi A Hoover
    Molecular Biology Production Group, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA
    Mar Biotechnol (NY) 9:411-9. 2007
    ..The application of genomics-based techniques and the integration of both biochemical and molecular data sets in marine organisms complement ongoing drug discovery efforts...
  18. ncbi Mensuration and cleaning of the jets in Andersen cascade impactors
    Mårten Svensson
    Analytical Development, AstraZeneca R and D Lund, SE 221 87 Lund, Sweden
    Pharm Res 22:161-5. 2005
    ..A cleaning method was suggested for stages with jets smaller than nominal diameters. The impact of nonapproved jet diameters on result parameters from particle size analysis was evaluated theoretically...
  19. ncbi Comparison of two approaches for treating cascade impaction mass balance measurements
    Bruce Wyka
    Schering Plough Research Institute, Summit, New Jersey, USA
    J Aerosol Med 20:236-56. 2007
    ....
  20. ncbi Revised internal volumes of cascade impactors for those provided by mitchell and nagel
    M Copley
    J Aerosol Med 18:364-6. 2005
  21. ncbi Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine
    Ahmad M Abdul-Fattah
    Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA
    Pharm Res 24:715-27. 2007
    ..To investigate the impact of drying method on the storage stability of dried vaccine formulations...
  22. pmc Cell membrane array fabrication and assay technology
    Victoria Yamazaki
    Synamem Corporation, 863 Mitten Road, Suite 101, Burlingame, CA 94010, USA
    BMC Biotechnol 5:18. 2005
    ..By contrast, arraying cell membranes in a manner which preserves their ability to mediate biochemical processes has been considerably more difficult...
  23. ncbi Ampicillin micronization by supercritical assisted atomization
    E Reverchon
    Universita di Salerno, Dipartimento di Ingegneria Chimica ed Alimentare, Via Ponte Don Melillo, 84084 Fisciano SA, Italy
    J Pharm Pharmacol 55:1465-71. 2003
    ..Moreover, by varying the solute concentration, ampicillin particles in a narrower range (1-3 microm) than that usually suggested for aerosol deliverable drugs were obtained. This is an example of particle size tailoring by SAA...
  24. ncbi Virtual drug discovery and development for neglected diseases through public-private partnerships
    Solomon Nwaka
    Medicines for Malaria Venture, Geneva, Switzerland
    Nat Rev Drug Discov 2:919-28. 2003
  25. ncbi A supercritical fluid-based coating technology. 3: preparation and characterization of bovine serum albumin particles coated with lipids
    I Ribeiro Dos Santos
    Unité de Vectorization Particulaire INSERM ERIT M 0104, 10, rue A Boquel, 49100 Angers Cedex, France
    J Microencapsul 20:110-28. 2003
    ..Furthermore, it was shown that BSA does not undergo any degradation after SC CO(2) treatment under the conditions used in the coating process...
  26. ncbi Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics
    Evangelos Karavas
    Pharmathen S A, Pharmaceutical Industry, Pallini Attikis, Attiki, Greece
    Eur J Pharm Biopharm 64:115-26. 2006
    ..028 C1.5, where C is the concentration of HPMC in the blend...
  27. ncbi Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin
    Weiling He
    University of Wyoming School of Pharmacy, Laramie, Wyoming 82071, USA
    J Pharm Sci 97:2250-9. 2008
    ..The oral bioavailability of Tp5 could be enhanced by PBCA nanoparticles. PBCA-Tp5-NP had the property of sustained-release and the efficacy of Tp5 was not changed after formulation...
  28. ncbi 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease
    David Pertuit
    Laboratory of Pharmaceutical Engineering EA3924, University of Franche Comte, Besancon, France
    J Control Release 123:211-8. 2007
    ..2+/-3.6 U/mg). NP formulations allowed to lower significantly the dose of 5ASA. These oral NP formulations demonstrated their therapeutic potential and appear to be an interesting approach for the therapy of inflammatory bowel disease...
  29. ncbi Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system
    Mauro Serratoni
    The School of Pharmacy, University of London, London, UK
    Eur J Pharm Biopharm 65:94-8. 2007
    ..Thus, the formulation approach offers the possibility of formulating and controlling the in vitro release of water-insoluble drugs from solid oral dosage forms...
  30. ncbi Adaptive neuro-fuzzy modeling of poorly soluble drug formulations
    Dionysios Douroumis
    Phoqus Pharmaceuticals Limited, 10 Kings Hill Avenue, Kings Hill, West Malling, Kent, ME19 4PQ, UK
    Pharm Res 23:1157-64. 2006
    ....
  31. ncbi Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles
    B Sarmento
    Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Porto, Porto, Portugal
    Eur J Pharm Biopharm 65:10-7. 2007
    ..The presented nanoparticulate system is a promising carrier for insulin oral delivery since it preserves insulin structure and therefore also, potentially, its bioactivity...
  32. ncbi A novel in situ forming drug delivery system for controlled parenteral drug delivery
    H Kranz
    College of Pharmacy, Freie Universitat Berlin, Kelchstr 31, 12169 Berlin, Germany
    Int J Pharm 332:107-14. 2007
    ..Therefore, the ISM systems are an attractive alternative to existing complicated microencapsulation methods...
  33. ncbi Effect of preparation conditions on the nutrient release properties of alginate-whey protein granular microspheres
    Lingyun Chen
    Institut de recherche sur les nutraceutiques et les aliments fonctionnels INAF STELA, Universite Laval, Sainte Foy, Canada
    Eur J Pharm Biopharm 65:354-62. 2007
    ..By careful process design, granular microspheres with potential as oral delivery vehicles for bioactive compounds may be developed...
  34. ncbi Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy
    Jinyoung Ko
    Biomedical Research Center, Korea Institute of Science and Technology, 39 1 Hawolgok Dong, Seongbuk gu, Seoul 136 719, South Korea
    J Control Release 123:109-15. 2007
    ....
  35. ncbi Low molecular weight heparin loaded pH-sensitive microparticles
    Yvette Meissner
    InsermU734 EA3452, Faculty of Pharmacy, Nancy, France
    Int J Pharm 335:147-53. 2007
    ..These microspheres represent a promising tool for the selective oral delivery of heparin to the colon, especially interesting in the treatment of inflammatory bowel disease...
  36. ncbi Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization
    Bin Lu
    West China School of Pharmacy, Sichuan University, Chengdu 610041, China
    Int J Pharm 333:87-94. 2007
    ..Pharmacokinetic study in rabbits showed that t(max) was delayed and C(max) lowered compared with tablets C and the values of AUC(0-24 h) of the three tablets were very close...
  37. ncbi Effects of drying technique on extrusion-spheronisation granules and tablet properties
    B Song
    University of Cambridge, Department of Chemical Engineering, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK
    Int J Pharm 332:38-44. 2007
    ..Both the voidage and dissolution characteristics are postulated to be determined by the microstructure established during drying...
  38. ncbi Effect of structural relaxation on the preparation and drug release behavior of poly(lactic-co-glycolic)acid microparticle drug delivery systems
    S Dean Allison
    Department of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, Columbia, South Carolina 29208, USA
    J Pharm Sci 97:2022-35. 2008
    ..Additional work is required to understand and control the relationship between microparticle processing, structural relaxation, and performance of PLGA microparticle drug delivery systems...
  39. ncbi Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres
    J L Arias
    Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada, Spain
    Int J Pharm 337:282-90. 2007
    ....
  40. ncbi Macromolecule release from monodisperse PLG microspheres: control of release rates and investigation of release mechanism
    Cory Berkland
    Department of Chemical and Biomolecular Engineering, University of Illinois, Urbana, Illinois 61801, USA
    J Pharm Sci 96:1176-91. 2007
    ..Monodisperse microspheres may represent a new delivery system for therapeutic proteins and DNA and provide enhanced control of delivery rates using simple injectable depot formulations...
  41. ncbi Microenvironmental pH modulation in solid dosage forms
    Sherif I Farag Badawy
    Bristol Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey, USA
    J Pharm Sci 96:948-59. 2007
    ..The incorporation of acidic pH modifiers in the controlled release formulation increases the solubility of the basic drug even as the high pH dissolution medium enters into the dosage form hence increasing drug release rate...
  42. ncbi Alginate/polymethacrylate copolymer microparticles for the intestinal delivery of enzymes
    Sarah Scocca
    Dipartimento di Scienze e Tecnologie Veterinarie per la Sicurezza Alimentare, Milano, Italia
    Curr Drug Deliv 4:103-8. 2007
    ..Residual enzymatic activity after the test remained satisfactory for both enzymes. In conclusion, these microparticle systems offer promise for applications in human and veterinary medicine as well as in human and animal nutrition...
  43. ncbi Comparison of neurofuzzy logic and decision trees in discovering knowledge from experimental data of an immediate release tablet formulation
    Q Shao
    Institute of Pharmaceutical Innovation, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
    Eur J Pharm Sci 31:129-36. 2007
    ..However, as decision trees are not able to deal with continuous dependent variables, data discretisation procedures are generally required...
  44. ncbi Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib
    Javed Ali
    Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar, New Delhi, India
    PDA J Pharm Sci Technol 61:88-96. 2007
    ..The correlation coefficient (R2 value) was obtained upon fitting the data to Higuchi equation, which signifies that the mechanism of release of celecoxib from the microspheres was diffusion rate-limited...
  45. ncbi Preparation and characterization of solid lipid nanoparticles loaded with total flavones of Hippophae rhamnoides (TFH)
    Dongkai Wang
    Shenyang Pharmaceutical University, Shengyang, Liaoning, China
    PDA J Pharm Sci Technol 61:110-20. 2007
    ..The advantages of TFH SLNs are the improved oral bioavailability of TFH and the prolonged mean retention time and drug release time...
  46. ncbi Role of nanotechnology in pharmaceutical product development
    Harikrishna Devalapally
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 110 Mugar Life Sciences Building, Boston, Massachusetts 02115, USA
    J Pharm Sci 96:2547-65. 2007
    ..This review summarizes some of the parameters and approaches that can be used to evaluate nanoparticulate drug delivery systems in early stages of formulation development...
  47. ncbi Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets
    Antonia Miranda
    Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain
    J Pharm Sci 96:2746-56. 2007
    ..This relationship is valid for different drugs, excipients and systems (inert or hydrophilic matrix tablets)...
  48. ncbi Controlling of systemic absorption of gliclazide through incorporation into alginate beads
    Raida S Al-Kassas
    Department of Pharmaceutics, College of Pharmacy, King Saud University, P O Box 17221, Riyadh 11484, Saudi Arabia
    Int J Pharm 341:230-7. 2007
    ..The results clearly demonstrated the ability of the system to maintain tight blood glucose level and improved the patient compliance by enhancing, controlling and prolonging the systemic absorption of gliclazide...
  49. ncbi Formulation of spray-dried phenytoin loaded poly(epsilon-caprolactone) microcarrier intended for brain delivery to treat epilepsy
    Zhuzhu Li
    Division of Pharmaceutical Sciences, University of Missouri Kansas City, 5005 Rockhill Road, Kansas City, Missouri 64110 2499, USA
    J Pharm Sci 96:1018-30. 2007
    ..These data suggested that PHT containing spray-dried PCL-microcarrier may be a promising drug delivery system for local brain delivery and long-term treatment of pharmacoresistant epilepsy...
  50. ncbi Investigation of an artificial intelligence technology--Model trees. Novel applications for an immediate release tablet formulation database
    Q Shao
    Institute of Pharmaceutical Innovation, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
    Eur J Pharm Sci 31:137-44. 2007
    ..However, additional and valuable knowledge hidden in the formulation database was extracted from these equations. It is concluded that, as a transparent technology, model trees are useful tools to formulators...
  51. ncbi A framework to investigate drug release variability arising from hypromellose viscosity specifications in controlled release matrix tablets
    Shawn A Mitchell
    Water Soluble Polymers, The Dow Chemical Company, Midland, Michigan 48674, USA
    J Pharm Sci 97:2277-85. 2008
    ..These predictions need to be validated experimentally...
  52. ncbi Polymer-surfactant nanoparticles for sustained release of water-soluble drugs
    Mahesh D Chavanpatil
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    J Pharm Sci 96:3379-89. 2007
    ..In conclusion, we have formulated a novel surfactant-polymer drug delivery carrier demonstrating sustained release of water-soluble drugs...
  53. ncbi Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release
    Yaxin Lu
    School of Pharmacy 32 mail box, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, Liaoning Province, PR China
    J Pharm Sci 96:3252-62. 2007
    ....
  54. ncbi Long acting porous microparticle for pulmonary protein delivery
    Min Jung Kwon
    Pharmaceutical and Health Research Institute, Amore Pacific Corporation R and D Center, 314 1, Bora dong, Giheung gu, Yongin si, Gyeonggi Do 446 729, Republic of Korea
    Int J Pharm 333:5-9. 2007
    ..In addition, it is expected that these particles arrive at a deep lung epithelium due to low density (high porosity) and limit macrophage recognition because of big particle size (more than 5 microm)...
  55. ncbi Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone
    Ian J Hardy
    Pharmaceutical Research and Development, Merck Sharp and Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
    Int J Pharm 337:246-53. 2007
    ..A validated mathematical model is also presented which allows drug release profiles to be reliably predicted based on the initial HPMC and PVP content in the tablet...
  56. ncbi N-phthaloylchitosan-g-mPEG design for all-trans retinoic acid-loaded polymeric micelles
    Praneet Opanasopit
    Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand
    Eur J Pharm Sci 30:424-31. 2007
    ..When compared to the unprotected ATRA, ATRA loaded in PLC-g-mPEG micelles was efficiently protected from photodegradation. This result suggested that loading of ATRA in micelles improved the chemical stability of ATRA...
  57. ncbi Theophylline granule formulation prepared by the wet granulation method: comparison of in vitro dissolution profiles and estimation of in vivo plasma concentrations
    E Karasulu
    Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ege, Bornova, Izmir, Turkey
    Eur J Drug Metab Pharmacokinet 31:291-8. 2006
    ..This study indicates that the dosage forms with similar in vitro dissolution profiles may have a similar in vivo performance, and that this performance could be estimated using appropriate correlation equations...
  58. ncbi Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules
    Mahesh D Chavanpatil
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    Pharm Res 24:803-10. 2007
    ..Here we report enhanced cellular delivery of water-soluble molecules using novel AerosolOT (AOT)-alginate nanoparticles recently developed in our laboratory...
  59. ncbi Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55
    Dorothea Sauer
    Drug Dynamics Institute, The University of Texas at Austin, Austin 78712, USA
    Eur J Pharm Biopharm 67:464-75. 2007
    ..The drug release rate was dependent both on TEC content and the coating level. The stability of the powder-coated CPM tablets was confirmed at 25 degrees C/60% RH over a storage time of 12 weeks...
  60. ncbi Practical considerations in development of solid dosage forms that contain cyclodextrin
    Lee A Miller
    Pfizer, Inc, Ann Arbor, Michigan 48105, USA
    J Pharm Sci 96:1691-707. 2007
    ....
  61. ncbi Basic butylated methacrylate copolymer/kappa-carrageenan interpolyelectrolyte complex: preparation, characterization and drug release behaviour
    H J Prado
    Departamento de Quimica Organica, Universidad de Buenos Aires, Buenos Aires, Argentina
    Eur J Pharm Biopharm 70:171-8. 2008
    ..These profiles could be controlled by conveniently modifying the proportion of the IPEC in the tablets...
  62. ncbi Study of the applicabilty of content uniformity and dissolution variation test on ropinirole hydrochloride tablets
    Edina Vranić
    Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
    Bosn J Basic Med Sci 8:193-200. 2008
    ..This may be a consequence of different assay techniques applied, HPLC, UV-D1 or UV...
  63. pmc Floating osmotic drug delivery system of ranitidine hydrochloride: development and evaluation--a technical note
    Pramod Kumar
    Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi 221005, U P, India
    AAPS PharmSciTech 9:480-5. 2008
  64. pmc A novel nanoparticle formulation for sustained paclitaxel delivery
    W J Trickler
    Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University Medical Center, 2500 California Plaza, Omaha, Nebraska 68178, USA
    AAPS PharmSciTech 9:486-93. 2008
    ..To develop a novel nanoparticle drug delivery system consisting of chitosan and glyceryl monooleate (GMO) for the delivery of a wide variety of therapeutics including paclitaxel...
  65. ncbi Drug release and swelling kinetics of directly compressed glipizide sustained-release matrices: establishment of level A IVIVC
    Jolly M Sankalia
    Centre of Relevance and Excellence in Novel Drug Delivery Systems, Pharmacy Department, The M S University of Baroda, G H Patel building, Donor s Plaza, Vadodara, Gujarat 390002, India
    J Control Release 129:49-58. 2008
    ..It was concluded that proper selection of rate-controlling polymers with release rate modifier excipients will determine overall release profile, duration and mechanism from directly compressed matrices...
  66. ncbi High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation
    T Nabais
    Faculty of Pharmacy, University of Montreal, Montreal, Que, Canada
    Eur J Pharm Biopharm 65:371-8. 2007
    ..In vivo studies demonstrate extended drug absorption, showing that the matrix tablets do not disintegrate immediately. Nevertheless, acetaminophen does not seem to be the most appropriate drug for this type of formulation...
  67. ncbi Control of burst release from nanogels via layer by layer assembly
    Jeremy P K Tan
    School of Mechanical and Aerospace Engineering, Nanyang Technological University, 50, Nanyang Avenue, Singapore 639798, Singapore
    J Control Release 128:248-54. 2008
    ..An empirical relationship describing the number of polyelectrolyte layers and time to attain steady-state drug concentration (tau(D)) was developed, where tau(D) increased with increasing polyelectrolyte layers...
  68. pmc Comparative study of propranolol hydrochloride release from matrix tablets with KollidonSR or hydroxy propyl methyl cellulose
    J Sahoo
    Royal College of Pharmacy and Health Sciences, Andhapasara Road, Berhampur 760002, Orissa, India
    AAPS PharmSciTech 9:577-82. 2008
    ..In conclusion, the in vitro release profile and the mathematical models indicate that release of propranolol hydrochloride can be effectively controlled from a single tablet using HPMC K15M or KollidonSR matrix system...
  69. pmc Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation
    Lingam Meka
    Novel Drug Delivery Systems Laboratory, University College of Pharmaceutical Sciences, Kakatiya University, Warangal 506009, Andhra Pradesh, India
    AAPS PharmSciTech 9:612-9. 2008
    ..The analysis of the parameter dissolution data after storage at 40 degrees C and 75% RH for 3 months showed, no significant change indicating the two dissolution profiles were considered to be similar (f2 value is more than 50)...
  70. ncbi Effect of formulation composition on the properties of controlled release tablets prepared by roller compaction
    Madhusudan Hariharan
    Pfizer Global R and D, Pharmaceutical Sciences, Skokie, Illinois, USA
    Drug Dev Ind Pharm 30:565-72. 2004
    ..These simple statistical tools can allow a formulator to rationally select levels of various components in a formulation, improve the quality of products, and develop more robust processes...
  71. pmc Formulation of controlled-release baclofen matrix tablets. II. Influence of some hydrophobic excipients on the release rate and in vitro evaluation
    Hamdy Abdelkader
    Department of Pharmaceutics, Minia University, Minia, Egypt
    AAPS PharmSciTech 9:675-83. 2008
    ..The release kinetics was found to be governed by the type and content of the excipients (polymer or filler). The prepared tablets showed no significant change in drug release rate when stored at ambient room conditions for 6 months...
  72. ncbi Water-free microencapsulation of proteins within PLGA microparticles by spray drying using PEG-assisted protein solubilization technique in organic solvent
    Hyejung Mok
    Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
    Eur J Pharm Biopharm 70:137-44. 2008
    ....
  73. ncbi Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose
    Tao Yi
    College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan 430074, China
    Eur J Pharm Sci 34:274-80. 2008
    ..Thus, it is possible to control the in vitro release of poorly soluble drugs from solid oral dosage forms containing SMES...
  74. ncbi The utility of cyclodextrins for enhancing oral bioavailability
    Rebecca L Carrier
    Department of Chemical Engineering, Northeastern University, 457 Snell Engineering Center, Boston, Massachusetts 02115, USA
    J Control Release 123:78-99. 2007
    ....
  75. pmc Preparation and evaluation of chitosan/carrageenan beads for controlled release of sodium diclofenac
    Pimwipha Piyakulawat
    Program of Petrochemistry and Polymer Science, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand
    AAPS PharmSciTech 8:E97. 2007
    ..The release of drug was controlled by the mechanism of the dissolution of DFNa in the dissolution medium and the diffusion of DFNa through the hydrogel beads...
  76. pmc Properties of pellets manufactured by wet extrusion/spheronization process using kappa-carrageenan: effect of process parameters
    Markus Thommes
    Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Dusseldorf, Germany
    AAPS PharmSciTech 8:E95. 2007
    ..The pellet properties are affected by the process parameters and the active pharmaceutical ingredient used...
  77. ncbi Characterization of pH- and temperature-sensitive hydrogel nanoparticles for controlled drug release
    Haiyan Chen
    Department of Biomedical Engineering, School of Life Science and Technology, China Pharmaceutical University, Shennong Road, Nanjing 210009, PR China
    PDA J Pharm Sci Technol 61:303-13. 2007
    ..In vitro release of 5-Fu from PNIPA-co-AA nanoparticle hydrogels was shown to be pH- and temperature-dependent, which demonstrated that the PNIPA-co-AA nanoparticles have great potential in the design of controlled drug delivery systems...
  78. ncbi Application of silicified microcrystalline cellulose (Prosolv) as a polymer carrier of Epilobium parviflorum Schreb. extract in oral solid drug form
    Zbigniew Marczyński
    Department of Applied Pharmacy, Medical University of Lodz
    Polim Med 37:21-32. 2007
    ..The tablets formed from E. parviflorum Schreb. extract with silicified microcrystalline cellulose (Prosolv SMCC 50) and croscarmellose sodium can be included into preparations of short dissolution time of the therapeutic substance...
  79. ncbi Influence of formulation and process parameters on the release characteristics of ethylcellulose sustained-release mini-matrices produced by hot-melt extrusion
    E Verhoeven
    Laboratory of Pharmaceutical Technology, Ghent University, Gent, Belgium
    Eur J Pharm Biopharm 69:312-9. 2008
    ..Simultaneously changing the powder feed rate (6-25-50 g/min) and screw speed (30-100-200 rpm) did not alter extrudate quality or dissolution properties...
  80. ncbi Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis
    Jiesheng Ye
    The School of Pharmaceutical Science, Shandong University, 44 Wenhua Xi Road, Ji Nan, Shandong Province, China
    Int J Pharm 352:273-9. 2008
    ..These results indicated that injectable actarit-loaded solid lipid nanoparticles were promising passive targeting therapeutic agents for rheumatoid arthritis...
  81. ncbi A novel system for three-pulse drug release based on "tablets in capsule" device
    Bin Li
    Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210038, PR China
    Int J Pharm 352:159-64. 2008
    ..However, lactose favored it. The results reveal that programmed drug delivery to achieve pulsatile drug release for three times daily can be obtained from these tablets in capsule system by systemic formulation approach...
  82. ncbi Release profile comparison and stability of diltiazem-resin microcapsules in sustained release suspensions
    Varaporn Buraphacheep Junyaprasert
    Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayutthaya Road, Bangkok 10400, Thailand
    Int J Pharm 352:81-91. 2008
    ..In addition, all sustained release suspensions possessed good stability with low drug leaching and their release profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 degrees C...
  83. pmc Formulation of controlled-release baclofen matrix tablets: influence of some hydrophilic polymers on the release rate and in vitro evaluation
    Hamdy Abdelkader
    Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt
    AAPS PharmSciTech 8:E100. 2007
    ....
  84. pmc Design and study of lamivudine oral controlled release tablets
    Punna Rao Ravi
    Pharmacy Group, Faculty Division III, Birla Institute of Technology and Science, Pilani, Rajasthan, India
    AAPS PharmSciTech 8:E101. 2007
    ..The developed controlled release matrix tablets of lamivudine, with good initial release (20%-25% in first hour) and extension of release up to 16 to 20 hours, can overcome the disadvantages of conventional tablets of lamivudine...
  85. pmc Estimation of the percolation thresholds in lobenzarit disodium native dextran matrix tablets
    Eddy Castellanos Gil
    Center of Pharmaceutical Chemistry, Calle 200, esq 21, Atabey, Playa, Havana, Cuba
    AAPS PharmSciTech 8:E115. 2007
    ..63% vol/vol of native dextran B110-1-2 plus initial porosity in the LBD-dextran matrices with a relative polymer/drug particle size of 4.17 were attributed to the existence of an excipient percolation threshold...
  86. pmc Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres
    Manju Rawat
    Institute of Pharmacy, Pt Ravishankar Shukla University, Raipur, C G 492010, India
    AAPS PharmSciTech 8:E116. 2007
    ..Thus, Eudragit S100 microspheres can be successfully prepared for oral delivery of enzymes with desirable characters in terms of maximum loading and diffusion release pattern...
  87. ncbi Activities of the Pharmaceutical Technology Institute of the Oswaldo Cruz Foundation with medicinal, insecticidal and insect repellent plants
    B Gilbert
    Fundação Oswaldo Cruz FIOCRUZ, Rio de Janeiro, Brazil
    An Acad Bras Cienc 71:265-71. 1999
    ..and other Phyllanthus species, insecticidal plants, Lonchocarpus urucu and Quassia amara, and the insect antifeedant plants Carapa guianensis and Pterodon emarginatus...
  88. ncbi [Chitosan in topical preparations]
    D Matusová
    Fakulta zdravotníckych specializacných stúdií SZU v Bratislave, Katedra farmaceutickej technológie, Slovenska republika
    Ceska Slov Farm 56:141-5. 2007
    Chitosan in topical preparations Within the framework of experimental work at the Department of Pharmaceutical Technology of Slovak Medical University, "insect" chitin obtained from the buff-tailed bumblebee (Bombus terrestris) was ..
  89. ncbi Application of polyglycolized glycerides in protection of amorphous form of etoricoxib during compression
    Shamkant Shimpi
    Department of Pharmaceutics, Bharati Vidyapeeth University, Poona College of Pharmacy, Maharashtra, India
    Chem Pharm Bull (Tokyo) 55:1448-51. 2007
    ..transition and stability problems during amorphous drug formulation are the major limiting factors in pharmaceutical technology. The purpose of the study was to evaluate the ability of polyglycolized glycerides (Gelucire) in ..
  90. ncbi Gastrointestinal transit in the common brushtail possum measured by gamma scintigraphy
    A McDowell
    School of Pharmacy, University of Otago, Dunedin, New Zealand
    Int J Pharm 302:125-32. 2005
    This paper reports an example of the application of pharmaceutical technology to wildlife management, specifically the design of an oral delivery system for the common brushtail possum in New Zealand...
  91. ncbi Mathematical modeling of drug delivery
    J Siepmann
    College of Pharmacy, JE 2491, University of Lille, 3 rue du Professeur Laguesse, 59006 Lille, France
    Int J Pharm 364:328-43. 2008
    ..computer simulations are likely to become an integral part of future research and development in pharmaceutical technology. Mathematical programs can be expected to be routinely used to help optimizing the design of novel ..
  92. ncbi Multiple micronutrient deficiencies: future research needs
    Rainer Gross
    Nutrition Section, Programme Division, UNICEF, 3 UN Plaza, New York, NY 10017, USA
    Food Nutr Bull 24:S42-53. 2003
    ..and efficacy, communications and behavior, effectiveness, cost-effectiveness (efficiency), and food and pharmaceutical technology. Attention to safety and surveillance for unintended adverse effects has acquired new relevance as we ..
  93. ncbi Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20
    Luisa Di Marzio
    Dept Scienze del Farmaco, University G D Annunzio, Via dei Vestini, 66100 Chieti, Italy
    Colloids Surf B Biointerfaces 82:18-24. 2011
    ..The present work led to a simple, but positive result in pharmaceutical technology area...
  94. ncbi [Pharmaceutical technology and pharmaceutical care in the dispensary]
    J P Remon
    Faculteit Farmaceutische Wetenschappen, Laboratorium voor Farmaceutische technologie, UGent, Harelbekestraat 72, B9000 Gent
    Verh K Acad Geneeskd Belg 69:131-48. 2007
    In this lecture the science 'Pharmaceutical Technology' was briefly elucidated, but the main part was about the concept of 'Pharmaceutical Care' in the community pharmacy...
  95. ncbi Investigations on mefenamic acid sustained release tablets with water-insoluble gel
    S Gungor
    Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, 34452 Beyazit, Istanbul, Turkey
    Farmaco 58:397-401. 2003
    ..Therefore, NaAL has been studied for preparing sustained release formulations in pharmaceutical technology. In this study, tablet formulations containing different ratios of NaAL and calcium gluconate (CaGL) ..
  96. ncbi The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems
    Angelica Vargas
    Department of Pharmaceutics and Biopharmaceutics, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 30, Quai Ernest Ansermet, CH 1211 Geneva 4, Switzerland
    Adv Drug Deliv Rev 59:1162-76. 2007
    ..assays that can be performed with chick embryos strengthen the interest of routinely using this model in pharmaceutical technology research...
  97. ncbi Content uniformity determination of pharmaceutical tablets using five near-infrared reflectance spectrometers: a process analytical technology (PAT) approach using robust multivariate calibration transfer algorithms
    Yusuf Sulub
    Analytical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, NJ 07936, United States
    Anal Chim Acta 611:143-50. 2008
    ..This scenario mimics the conventional pharmaceutical technology transfer from research and development to production...
  98. ncbi Development of a novel nanocapsule formulation by emulsion-diffusion combined with high hydrostatic pressure
    Mi Yeon Lee
    Universite de Lyon, Lyon, France
    J Microencapsul 26:122-9. 2009
    A common method used to prepare polymeric nanoparticles in pharmaceutical technology is emulsion-diffusion. However, this method has several disadvantages due to the long duration of the process...
  99. ncbi Development and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzyme
    Manju Rawat
    Institute of Pharmacy, Pt Ravishankar Shukla University, Raipur C G, India
    Drug Dev Ind Pharm 34:181-8. 2008
    ..drugs by oral route maintaining their active conformation remains a key challenge in the field of pharmaceutical technology. In the present study, we propose the use of a nanosize ceramic core-based system for effective oral ..
  100. ncbi The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates
    Jidong Wang
    Department of Radiation Oncology, Cancer Center, Peking University Third Hospital, Beijing, China
    Cancer Biother Radiopharm 24:409-16. 2009
    The relative biologic effectiveness of model 6711 125I seeds (Ningbo Junan Pharmaceutical Technology Company,Ningbo, China) and their effects on growth, cell cycle, and apoptosis in human pancreatic cancer cell line PANC-1 were examined ..
  101. ncbi [Development of a multidimensional system for classification and management of health information: applying to clinical information]
    Ana Cristina Rama
    Serviços Farmacêuticos, Hospitais da Universidade de Coimbra
    Acta Med Port 20:567-74. 2007
    ..The objective is to test the applicability and capacity for retrieval of a multidimensional system developed for classification and management of health information...

Research Grants66

  1. Development of an Oral Anthrax Vaccine
    John Hilfinger; Fiscal Year: 2002
    ..We feel that development of this technology for oral vaccines will have an immediate impact in the area of anthrax vaccine and will also have utility for a wide variety of other vaccines. ..
  2. CROSSLINKED LIPOSOMES AS PARTICULATE DRUG CARRIERS
    Moo Cho; Fiscal Year: 1992
    ..Developmental efforts have been, however, greatly hampered from the lack of pharmaceutical technology of producing a stable suspension product for systemic administration...
  3. ORAL MUCOSITIS - FORMULATIONS FOR PALLIATION AND THERAPY
    Christopher Squier; Fiscal Year: 2002
    ..The study will involve collaborative studies between investigators with expertise in pharmaceutical technology, oral mucosal biology and oral medicine so as to develop palliative and therapeutic approaches to ..
  4. Novel Dendritic Cell Chemoattractant and Receptor
    Eugene Butcher; Fiscal Year: 2009
    ..abstract_text> ..
  5. Development of a SARS Coronavirus Vaccine
    Jeffrey Ulmer; Fiscal Year: 2004
    ..An extension of these during the final stages of Specific Aim 4. ..
  6. Conference on Leukocyte Trafficking
    Eugene Butcher; Fiscal Year: 2004
    ..abstract_text> ..
  7. COMPUTER-AIDED DESIGN, SYNTHESIS, AND TESTING OF A NOVEL FAMILY OF TRIAZOLE-BASED
    Sean Ekins; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  8. Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases
    Sean Ekins; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  9. Effects of Probiotic Lactobacilli on Rotavirus Immunity
    Lijuan Yuan; Fiscal Year: 2006
    ..The findings from this study will also facilitate an understanding of the potential adjuvant effects of probiotics for development of more effective vaccines against rotavirus and other enteric virus-induced diseases. ..
  10. DerG (a new immunomodulator) Treatment of Viral Encepha*
    KENNETH ROSENTHAL; Fiscal Year: 2005
    ....
  11. MECHANISMS OF RESPONSE TO PULMONARY VACCINATION
    Anthony Hickey; Fiscal Year: 2005
    ..The significance of this work lies in the novelty of pulmonary vaccination for the treatment of tuberculosis and the knowledge of the immune response gained from targeted antigen delivery to the lungs. ..
  12. ENDOTHELIAL CELL BIOLOGY IN INFLAMMATION
    Eugene Butcher; Fiscal Year: 2008
    ..The proposed studies should expand our understanding of the critical role of the vascular endothelium in regulating lymphocyte trafficking during normal and pathologic immune responses. ..
  13. VASCULAR-MONOCYTE ADHESION MOLECULE IN ATHEROGENESIS
    Eugene Butcher; Fiscal Year: 2002
    ..The proposed studies will elucidate the structure of this novel vascular receptor and its role in monocyte recruitment in atherogenesis. They may lead to new approaches to the regulation of the atherogenic process. ..
  14. CHEMOATTRACTANT SIGNALING TO LEUKOCYTE INTEGRINS
    Eugene Butcher; Fiscal Year: 2001
    ..These studies should define signaling mechanisms regulating the adhesion of leukocytes and other cells, and may lead to novel therapeutic approaches for the control of neoplastic and inflammatory diseases ..
  15. Tolerogenic DC as Therapeutic Agents in GVHD
    Eugene C Butcher; Fiscal Year: 2010
    ..Together, these studies will define in detail the potential of CCR9+ pDCs to suppress deleterious effects of GVHD in settings modeling situations in which human patients encounter pathogenic GVHD responses. ..
  16. Intestinal Lymphocyte Trafficking
    Eugene Butcher; Fiscal Year: 2009
    ....
  17. 2nd Annual Vaccine Renaissance Conference, RI
    Anne De Groot; Fiscal Year: 2006
    ..More than 80 participants attended that 1st conference from the[unreadable] New England region and beyond. ..
  18. MULTIFUNCTIONAL STIMULI-SENSITIVE PHARMACEUTICAL NANOCARRIERS
    Vladimir P Torchilin; Fiscal Year: 2010
    ....
  19. INHALATIONAL ANESTHETIC BINDING STUDIES
    Roderic Eckenhoff; Fiscal Year: 2007
    ..abstract_text> ..
  20. NOVEL NONPEPTIDE LIGANDS FOR THE OPIOID RECEPTORS
    Subramaniam Ananthan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  21. Development of Novel Antiviral Agents VS West Nile Virus
    Michael Diamond; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  22. Role of Oxidants & Angiogenesis in Kaposi's Sarcoma
    Susan Mallery; Fiscal Year: 2007
    ..Elucidation of these interactions will not only clarify KS pathogenic mechanisms, but will also identify sites for KS therapeutic intervention. ..
  23. Statewide Implementation of Electronic Health Records
    David Bates; Fiscal Year: 2006
    ..Dissemination of the results of this work should speed efforts toward the establishment of a national health information infrastructure. [unreadable] [unreadable]..
  24. Evaluating Trichophyton tonsurans Carriage and Infection
    Susan Abdel Rahman; Fiscal Year: 2006
    ..abstract_text> ..
  25. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2010
    ..This will allows us to effectively screen a large number of unique primary Env antigens to formulate the effective polyvalent HIV vaccines for the next phase of clinical testing. ..
  26. Fourth International Nanomedicine and Drug Delivery Symposium
    Alexander Kabanov; Fiscal Year: 2006
    ..In the final analysis achieving the aim of the conference will contribute to the development of novel nanoscale delivery technologies for diagnostics and therapeutics that address unmet clinical needs. [unreadable]..
  27. HPLC time-of-flight mass spectrometer for accurate mass measurements
    Richard van Breemen; Fiscal Year: 2007
    ..to natural product chemists and synthetic organic chemists in the user community who rely upon rapid analyses of their compounds in order to advance with their NIH-funded research programs [unreadable] [unreadable] [unreadable]..
  28. Neurofibrillary Tangle-Induced Dementia in AD
    Travis Dunckley; Fiscal Year: 2008
    ..Successful completion of this proposal will yield numerous novel targets for potentially efficacious therapeutic intervention in Alzheimer's disease. [unreadable] [unreadable]..
  29. COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION
    Frank Carroll; Fiscal Year: 2007
    ..abstract_text> ..
  30. PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*
    George Brewer; Fiscal Year: 2007
    ..Abstract Not Provided ..
  31. The roles of apolipoprotein A-IV structure and lipid affinity in its function
    W Davidson; Fiscal Year: 2009
    ....
  32. Apolipoprotein-mediated cholesterol efflux
    W Davidson; Fiscal Year: 2008
    ..This understanding will form a basis for new interventions designed to enhance apolipoprotein-mediated cholesterol efflux from cells, particularly those within the atherosclerotic vessel wall. ..
  33. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2006
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. [unreadable] [unreadable]..
  34. MICELLAR CARRIERS FOR SPARINGLY SOLUBLE PHARMACEUTICALS
    Vladimir Torchilin; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  35. Functional Roles of Integrins in Modulating Neural Responses of Mechanically Sens
    Michael Hadjiargyrou; Fiscal Year: 2007
    ..Results obtained will further our understanding of the molecular and cellular events involved in mechanotransduction by cutaneous mechanoreceptors. [unreadable] [unreadable]..
  36. Cross-linked Polymer Micelles in Cancer Therapy
    Tatiana K Bronich; Fiscal Year: 2010
    ..It is anticipated that these studies will lead to the design of new formulation of cisplatin for improved cancer treatment. ..
  37. A Genome-Derived, Epitope-Driven H. Pylori Vaccine
    Anne De Groot; Fiscal Year: 2006
    ..pylori disease as our correlate of efficacy. ..
  38. Novel Smallpox Vaccine Derived from VV/VAR Immunome
    Anne De Groot; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  39. FRA16D CHROMOSOMAL FRAGILE SITE IN LIVER CARCINOGENESIS
    Lewis Roberts; Fiscal Year: 2003
    ..This will enable me to obtain the training and preliminary data I need to launch an independent, productive research career. ..
  40. MICROCHIP DRUG DELIVERY SYSTEM
    Robert Langer; Fiscal Year: 2003
    ..abstract_text> ..
  41. Intelligent Information Systems for Systems Biology
    Leroy Hood; Fiscal Year: 2003
    ..Finally, we propose some novel educational programs designed to put graduate students together into interdisciplinary teams for problem solving. ..
  42. ANGIOGENESIS INHIBITORS FROM SHARK CARTILAGE
    Robert Langer; Fiscal Year: 2003
    ..After screening in the in vitro assays mentioned above, potential anti-angiogenic activity from shark cartilage will be assayed in vivo using the chick chonoallantoic assay and the rabbit corneal pocket assay. ..
  43. FAT MEDIATED INSULIN SECRETION AND DIABETES IN ELDERLY
    Guenther Boden; Fiscal Year: 2003
    ..We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM. ..
  44. Novel inhibitors of M. tuberculosis RNA Polymerase
    Anthony Lynch; Fiscal Year: 2003
    ..Phase II studies would thereafter be addressed toward systematic optimization of the series as an antitubercular agent. ..
  45. CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Mark Ratain; Fiscal Year: 2002
    ..Since many of the studies include analysis of pharmacological specimens, the Committee utilizes three core laboratories--at the University of Chicago, the University of Maryland and the University of Tennessee. ..
  46. GENE THERAPY FOR ARTHRITIS IN THE TNFA-TRANSGENIC MOUSE
    Edward Schwarz; Fiscal Year: 2002
    ..abstract_text> ..
  47. CONTROLLED RELEASE OF MACROMOLECULES
    Robert Langer; Fiscal Year: 2001
    ..The long-term objectives of this research are to develop robust DNA stabilization methods to meet the pharmaceutical requirements for controlled release gene delivery systems. ..
  48. NOVEL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE
    Frank Carroll; Fiscal Year: 2001
    ..An ideal candidate compound would not only have efficacy in the preclinical models but would be safe, orally active, and potent, would not show tolerance or sensitization, and if abusable, would be less so than cocaine. ..
  49. Ultrasound Polymeric Drug Delivery
    Robert Langer; Fiscal Year: 2001
    ..4. Mathematical modeling of transdermal transport during LFS: Specifically, develop mathematical models to quantitatively predict the effect of ultrasound on transdermal transport and skin barrier recovery after sonophoresis. ..
  50. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2004
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  51. The Bioavilaibility of Folate in Humans
    Richard van Breemen; Fiscal Year: 2004
    ..Our new LC-MS-MS assay and the use of 13C-labeled folate species will provide new and more detailed information on the uptake, metabolism, and bioavailability of folates than has been possible previously. ..
  52. Smoking Cessation for Head and Neck Cancer Patients
    Robert Schnoll; Fiscal Year: 2006
    ..In turn, our findings may help guide the implementation of smoking cessation treatments for all cancer patients within Comprehensive Cancer Centers in the US. ..
  53. Effect of Viral Escape on Memory T Cell Maturation
    RAFICK PIERRE SEKALY; Fiscal Year: 2006
    ..Overall, we will be able to assess the importance of Ag specific CD4+ memory T cells and of viral escape in the maintenance of persistence CTL response. [unreadable] [unreadable]..
  54. Screen for Quorum Sensing Molecular Inhibitors (RMI)
    Vanessa Sperandio; Fiscal Year: 2005
    ....
  55. Nicotinic-Antipsychotic Drug Interactions and Cognition
    Edward Levin; Fiscal Year: 2006
    ..abstract_text> ..
  56. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
    Anne De Groot; Fiscal Year: 2005
    ..abstract_text> ..
  57. Chemoprevention of Oral Dysplasia by Black Raspberries
    Susan Mallery; Fiscal Year: 2005
    ..This experimental design (comparison of pretreatment and post-treatments tissues) permits each patient to serve as their own internal control. ..
  58. 2D-HPLC-Tandem Mass Spectrometer for Proteomics
    Richard van Breemen; Fiscal Year: 2005
    ..Overall, the proposed 2D mu LC-MS/MS instrument will complement the existing proteomics resources on campus and will enhance the current research of NIH-funded users by providing analytical capabilities currently unavailable on campus. ..
  59. Elucidation of the Lipoxygenase-Mediated Pathway of Lun*
    PAUL MYRDAL; Fiscal Year: 2005
    ..abstract_text> ..
  60. MATRIX-ASSISTED LASER DESORPTION TOF MASS SPECTROMETER
    Richard van Breemen; Fiscal Year: 2001
    ..abstract_text> ..
  61. REGULATION OF BBB GLUT1 GLUCOSE TRANSPORTER
    William Pardridge; Fiscal Year: 2002
    ..These studies will provide insight into molecular mechanisms of regulation of a step crucial to the maintenance of cerebral intermediary metabolism, i.e., the continuous transport of glucose across the blood-brain barrier in vivo. ..
  62. Non-Viral Gene Targeting to the Brain
    William Pardridge; Fiscal Year: 2008
    ..abstract_text> ..
  63. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  64. Antisense imaging of brain gene expression in vivo
    William Pardridge; Fiscal Year: 2005
    ..This technology could be extended to humans and to other organs. At present, there is no parallel technology that enables the non-invasive in vivo imaging of "any gene in any person," which is the goal of this work. ..
  65. BLOOD BRAIN BARRIER LARGE NEUTRAL AMINO ACID TRANSPORTER
    William Pardridge; Fiscal Year: 2003
    ..These studies will provide new molecular biological information on a crucial transporter at the blood-brain barrier that regulates the supply in the brain of essential amino acids. ..
  66. AIDS Neurotherapeutics and BBB Drug Efflux
    William Pardridge; Fiscal Year: 2007
    ..This work provides the basis for future drug discovery of AET blockers, which can be used as co-drugs to increase CNS penetration of HAART drugs. ..